Hematology Reading List

Disorders of Red Blood Cells

Click on an underlined citation to view the article

Management of sickle cell disease.
Steinberg, M. H., N. Engl. J. Med. 340:1021-1030, 1999.
Causes and outcomes of the acute chest syndrome in sickle cell disease.
Vichinsky, E. P. et al., N. Engl. J. Med. 342:1855-1865, 2000.
The acute chest syndrome of sickle cell disease.
Platt, O. S., N. Engl. J. Med. 342:1904-1907, 2000.
The painful crisis of homozygous sickle cell disease: clinical features.
Serjeant, G. R. et al., Br. J. Haematol. 87:586-591, 1994.
Mortality in sickle cell disease: life expectancy and risk factors for early death.
Platt, O. S. et al., N. Engl. J. Med. 330:1639-1644, 1994.
Haematological care of the Johovah's Witness patient.
Marsh, J. C. W., and Bevan, D., Br. J. Haematol. 119:25-37, 2002.
Disorders of iron metabolism.
Andrews, N. C., N. Engl. J. Med. 341:1986-1995, 1999.
Clinical use of the total dose intravenous infusion of iron dextran.
Auerbach, M. et al., J. Lab. Clin. Med. 111:566-570, 1988.
Practical management of iron overload.
Porter, J.B., Br. J. Haematol. 115:239-252, 2001.
The Porphyrias.
Perlroth, M. G., Scientific American Medicine 9 Metab:1-12, 1988.
Laboratory diagnosis of the porphyrias.
Kushner, J. P., N. Engl. J. Med. 324:1432-1434, 1991.

The World Health Organization (WHO) classification of the myeloid neoplasms.
Vardiman, J. W. et al., Blood 100:2292-2302, 2002.
Acquired aplastic anemia.
Young, N.S., Ann. Intern. Med. 136:534-546, 2002.
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Kurzrock, R. et al., Ann. Intern. Med. 138:819-830, 2003.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman, J. M. and Melo, J. V., N. Engl. J. Med. 344:1084-1086, 2001.
Myelodysplasia.
Heaney, M. L. and Golde, D. W., N. Engl. J. Med. 340:1649-1660, 1999.
Myelofibrosis with myeloid metaplasia.
Tefferi, A., N. Engl. J. Med. 342:1255-1265, 2000.
A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi, A. et al., Am. J. Med. 109:141-149, 2000.
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle, R. A. et al., N. Engl. J. Med. 346:564-569, 2002.
Multiple myeloma.
Bataille, R. and Harousseau, J.-L., N. Engl. J. Med. 336:1657-1664, 1997.
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
Kumar, A. et al., Lancet Oncol. 4:293-304, 2003.
Neuropathies associated with paraproteinemia.
Ropper, A. H. and Gorson, K. C., N. Engl. J. Med. 338: 1601-1607, 1998.
Chronic lymphocytic leukemia.
Rozman, C. and Montserrat, E., N. Engl. J. Med. 333:1052-1057, 1995.
When and how to treat chronic lymphocytic leukemia.
Dighiero, G. and Binet, J.-L., N. Engl. J. Med. 343:1799-1801, 2000.

Drug-induced thrombocytopenia: a systematic review of published case reports.
George, J. N. et al., Ann. Intern. Med. 129:886-890, 1998.
The clinical importance of acquired abnormalities of platelet function.
George, J. N. and Shattil, S. J., N. Engl. J. Med. 324:27-39, 1991.
Immune thrombocytopenic purpura.
Cines, D. B. and Blanchette, V., N. Engl. J. Med. 346:995-1008, 2002.
Thrombotic microangiopathies.
Moake, J. L., N. Engl. J. Med. 347:589-600, 2002.
How I treat patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome.
George, J. N., N. Engl. J. Med. 347:589-600, 2002.

A practical guide to the evaluation and treatment of hemophilia.
Furie, B. et al., Blood 84:3-9, 1994.
Hemostatic drugs.
Mannucci, P. M., N. Engl. J. Med. 339:245-253, 1998.
Hemostasis/Platelets.
Sadler, J. E., Foster, P. A., and George, J. N., Hematology (Education Program of the American Society of Hematology), p. 79-87, 1996.
How I treat patients with von Willebrand disease.
Mannucci, P. M., Blood 97:1915-1919, 2001.
Disseminated intravascular coagulation.
Levi, M. and ten Cate, H., N. Engl. J. Med. 341:586-592, 1999.

Genetic susceptibility to venous thrombosis.
Seligsohn, U. and Lubetsky, A., N. Engl. J. Med. 344:1222-1231, 2001.
The thrombophilias: well-defined risk factors with uncertain therapeutic implications.
Bauer, K. A., Ann. Intern. Med. 135:367-373, 2001.
How we diagnose and treat deep vein thrombosis.
Hirsh, J. and Lee, A. Y. Y., Blood 99:3102-3110, 2002.
Management of anticoagulation before and after elective surgery.
Kearon, C. and Hirsh, J., N. Engl. J. Med. 336:1506-1511, 1997.
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism.
Dolovich, L. R. et al., Arch. Intern. Med. 160:181-188, 2000.
The antiphospholipid syndrome.
Levine, J. S. et al., N. Engl. J. Med. 346:752-763, 2002.
Heparin-induced thrombocytopenia: pathogenesis and management.
Warkentin, T. E., Br. J. Haematol. 121:535-555, 2003.
How I treat heparin-induced thrombocytopenia and thrombosis.
Alving, B. M., Blood 101:31-37, 2003.
Vena cava filters: a comprehensive review.
Streiff, M. B., Blood 95:3669-3677, 2000.

Blood transfusion.
Goodnough, L. T. et al. , N. Engl. J. Med. 340:438-447, 1999.
The haematological features of HIV infection.
Bain, B. J., Br. J. Haematol. 99:1-8, 1997.
Venous thromboembolism during pregnancy.
Toglia, M. R. and Weg, J. G., N. Engl. J. Med. 335:108-114, 1996.
How we manage venous thromboembolism during pregnancy.
Bates, S. M. and Ginsburg, J.S., Blood 100:3470-3478, 2002.
Management of idiopathic thrombocytopenic purpura in pregnancy.
Gill, K. K. and Kelton, J. G., Semin. Hematol. 37:275-289, 2000.